Literature DB >> 17505216

The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives.

Hilary H Colwell1, Susan D Mathias, Nita H Ngo, Matthew Gitlin, Z John Lu, Teresa Knoop.   

Abstract

Cancer patients treated with parenteral chimeric or humanized monoclonal antibody agents or chemotherapy are at risk of experiencing an infusion reaction. The impact of infusion reactions can be substantial. Infusion reactions, even when mild, can be disruptive and stressful. In-person interviews with 202 nurses were conducted at the 2005 Annual Oncology Nursing Society Congress to evaluate the impact of infusion reactions on patients and nurses in the inpatient and outpatient practice settings. Results from this survey study suggest that infusion reactions have a significant negative impact on both patients and nurses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505216     DOI: 10.1097/01.NAN.0000270674.13439.5b

Source DB:  PubMed          Journal:  J Infus Nurs        ISSN: 1533-1458


  5 in total

1.  Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment.

Authors:  Carissa Laudati; Caroline Clark; Andrea Knezevic; Zhigang Zhang; Margaret Barton-Burke
Journal:  Clin J Oncol Nurs       Date:  2018-08-01       Impact factor: 1.027

Review 2.  Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.

Authors:  Xue Song; Stacey R Long; Beth Barber; Cheryl A Kassed; Marcus Healey; Clare Jones; Zhongyun Zhao
Journal:  Curr Clin Pharmacol       Date:  2012-02-01

3.  A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature.

Authors:  Patricia A Demoor; Yuri Matusov; Colleen Kelly; Shobha Kolan; Linda Barnachea; Lyudmila A Bazhenova
Journal:  J Cancer       Date:  2011-03-10       Impact factor: 4.207

4.  Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab.

Authors:  K A Foley; P F Wang; B L Barber; S R Long; J E Bagalman; V Wagner; X Song; Z Zhao
Journal:  Ann Oncol       Date:  2010-01-25       Impact factor: 32.976

5.  Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab.

Authors:  Christina Theodore-Oklota; Louise Humphrey; Christof Wiesner; Gabriel Schnetzler; Stacie Hudgens; Alicyn Campbell
Journal:  Patient Prefer Adherence       Date:  2016-09-13       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.